List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Canavan Disease - Overview
Canavan Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Canavan Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Canavan Disease - Companies Involved in Therapeutics Development
Aspa Therapeutics Inc
Orphan Star Therapeutics LLC
Pfizer Inc
Canavan Disease - Drug Profiles
BBP-812 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Target Aspartoacylase for Canavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy 2 to Activate Aspartoacylase for Canavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzyme to Replace Aspartoacylase for Canavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Canavan Disease - Dormant Projects
Canavan Disease - Discontinued Products
Canavan Disease - Product Development Milestones
Featured News & Press Releases
Oct 22, 2019: BridgeBio Pharma presents on its Central Nervous drug candidate BBP-812 at the European Society of Gene and Cell Therapy Conference
Nov 09, 2017: New gene therapy developed with UNSW researchers targets brain disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Canavan Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Canavan Disease - Pipeline by Aspa Therapeutics Inc, H2 2019
Canavan Disease - Pipeline by Orphan Star Therapeutics LLC, H2 2019
Canavan Disease - Pipeline by Pfizer Inc, H2 2019
Canavan Disease - Dormant Projects, H2 2019
Canavan Disease - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Canavan Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

Companies Mentioned
• Aspa Therapeutics Inc
• Orphan Star Therapeutics LLC
• Pfizer Inc